Prostate cancer is the leading male cancer worldwide. There remains a controversy as to which patients have indolent disease and which patients present an aggressive disease needing treatment with intent to cure. Because of quality of life impairment associated with treatment by radiation or surgery, active surveillance (AS) is a valid management option to avoid or differ aggressive treatment. Traditionally, AS was reserved for men with low risk prostate cancer, however intermediate risk patients are more and more found in AS cohorts. The aim of this review is to describe the place of AS in intermediate risk patients and the perspectives offered by such a treatment modality.
Introduction
Prostate cancer is the leading non-cutaneous male cancer in the US with an estimated incidence of 238,590 and a disease related deaths reaching 29,720 in 2013 [1] . These figures-a high incidence and steadily following age-specific mortality-are the consequence of a steady downward stage migration since the approval of the prostate specific antigen (PSA) test by the Food and Drug Administration of the United States in the mid-1990s and its subsequent wide use [2] . In the face of screening, most tumors are diagnosed at an organ-confined stage with excellent long-term survival [1] . In fact, most men with prostate cancer die of other causes like cardiovascular disease and aging related morbidities rather than prostate cancer and a relatively small minority of prostate cancers ultimately prove lethal [3] .
Due to the repeated use of PSA testing, prostate cancer has been increasingly diagnosed with early stage, low risk disease as determined by the PSA, Gleason score, and other parameters. A study of the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database found that among the 10,385 patients, 4232 (41.6%), 2761 (26.6%), and 3301 (31.8%) had low, intermediate, and high risk prostate cancer at diagnosis, respectively [4] . This finding is consistent with a more recently published paper in a Scandinavian cohort where the very low risk accounted for 46% of the cohort (n = 57,713) [5] . The multiplicity of prostate cancer risk assessment tools, including several intended to identify indolent tumors [6] - [11] , reflects a lack of consensus on precisely how to distinguish between aggressive and indolent disease.
This uncertainty, combined with significant rates of upgrading and upstaging among men initially thought to have low-risk disease [12] , fuels anxiety which helps drive men toward aggressive management of lower risk tumors [13] . Subsequently, we observe high rates of aggressive treatments of these patients with low-risk, localized disease [14] therefore exposing them to the risks of treatment related morbidity and quality of life impact [15] [16] . In fact, many prostate cancers would never cause any impairment to quality or quantity of life if they remained undetected and are thus said to be over-diagnosed [17] . In 2012, the US Preventive Services Task Force released a recommendation that all PSA-based screening should be ended [18] , a policy that would reduce over diagnosis but at the price of dramatic increases in cancer-specific morbidity and mortality [19] .
Recently in Sweden, Loeb et al. [5] analyzed the contemporary trends of prostate cancer management. Using the National Prostate Cancer Register they found that for the period 2007-2011, 16 .1% (n = 13,030) of men with intermediate risk elected to be on Active Surveillance compared to 58.9% (n = 4594) of men with low risk. This finding favor a trend towards a higher utilization of AS and in logistic regression the only factor associated with Active Surveillance in intermediate risk men was never being married while in the low risk group a higher education was associated with Active Surveillance use.
A far better solution to the problems of over diagnosis and overtreatment is selective screening of men with good life expectancy, with the clear understanding that the purpose of screening is the early identification and targeted treatment of higher-risk disease. For the larger numbers of men diagnosed with low-risk tumors, on the other hand, a growing consensus supports deferring immediate treatment in favor of active surveillance (AS) [20] . AS aims at monitoring carefully the patients with serial PSA assessments, repeat biopsies, and other tests intended to identify early signs of progression. If and when such progression is noted, the patient undergoes treatment. Such delayed treatment, when needed, is done within a window of opportunity for cure often measurable in many years, without compromising long term outcomes in carefully selected patients [21] [22] to the most permissive (Royal Marsden definition) [24] . Despite the promising role of AS in prostate cancer management, however, its uptake is still low. In fact in the United States, only 10% of patients eligible for AS chose this option [20] .
In an effort to evaluate the benefit of active treatment over observation, the Prostate Cancer intervention versus observation trial (PIVOT), an ongoing study is promising and yet has important findings. In this study, patients were randomly assigned to surgery or observation and at 10 years (median) follow-up.
In patients with low-risk disease men, there was no significant difference between the two treatment groups in all-cause or prostate cancer-specific mortality overall. Conversely, in the high-risk disease men, there were significantly fewer deaths from prostate cancer or from any cause in the surgery group compared to their observed counterpart [25] . While the PIVOT study provides evidence fa- years follow up will provide further evidence [26] .
Using data from the Johns Hopkins prostate cancer patient Xia et al. [27] found that the absolute difference between prostate cancer mortality under surveillance or immediate radical prostatectomy is likely to be modest which is similar to the PIVOT findings. as the only criteria [31] . The criteria that put the patients in the intermediate group appear to be important again underlying the mosaic of men in this group.
Disease Progression in AS
The same study found a trend toward more adverse pathologic outcomes for pa- There are controversies as to the role of tumor volume in predicting the outcomes after radical prostatectomy (RP). At UCSF, Porten et al. [33] 
AS and Intermediate Risk Men
One key question in AS is determining eligibility for surveillance. avoid treatment, however, and are willing to accept these risks they are offered a trial of AS. A report from the UCSF cohort, for example, identified 90 men considered to be at intermediate risk [23] . Compared with those with low-risk disease, men with intermediate-risk were older and had higher baseline PSA levels (mean, 10.9 vs. 5.1 ng/mL). They had more rapid PSA kinetics, and among those ultimately undergoing surgery, they were more likely to be upstaged; however neither of these differences were statistically significant. The likelihood of progression did not differ between low risk and intermediate risk men with the caveat that it is easier for a man with low-risk Gleason 3 + 3 to progress to Gleason 3 + 4 than for an intermediate-risk Gleason 3 + 4 tumor to progress to 4 + 3.
Men not meeting strict criteria for low risk prostate cancer were also found in other cohorts like the Johns Hopkins cohort. In that study the rates of progression to active treatment were higher for men not meeting strict criteria for AS (clinical stage T1c, PSAD < 0.15 ng/mL, Gleason ≤ 6, ≤ 2 cores with cancer, and ≤ 50% involvement of any core with cancer) compared to those meeting these criteria (40% vs. 31%; P = 0.03), and the rates of upgrading or increase in tumor volume were also higher in men not meeting the strict criteria for inclusion in AS [37] . One particularity of this study was that 136 men (17.7%) of the cohort did not meet AS criteria due the PSA density while only 30 men (3.9%)
failed to meet another very-low-risk disease criterion. Conversely in the UCSF cohort, the major difference between low risk and intermediate risk men was related to the Gleason score with 376 men having Gleason 2 to 6 and CAPRA 0 to 2 (low risk), and 90 men having Gleason 7 and/or CAPRA 3 to 5 (intermediate risk) [23] .
In the University of Toronto AS cohort, between 1995 and 1999 the study was offered to all favorable-risk patients (i.e., Gleason 6 or less, PSA 10 ng/ml or less) and to patients older than 70 years with PSA up to 15 ng/ml or Gleason up to 3 + 4. Since January 2000, the study was restricted to favorable-risk patients only.
Among 450 patients of the study, there were 85 patients (18.9%) who were intermediate risk at baseline, defined as either PSA > 15 ng/mL, Gleason 7, or stage T3. On those, 49 patients (11%) remained untreated, and 36 patients (8%) were eventually treated. Of the 49 untreated, no patient had disease progression and of the 36 who were treated, only one had experienced progression to metastatic disease and death [38] .
The largest AS cohort of intermediate risk men was recently published by Loeb et al. [5] . This study was conducted using the unique Swedish prostate cancer registry. 
Perspectives
More research is needed to better determine the place of active surveillance in well-selected intermediate risk prostate cancer. It is possible that this treatment modality is extended due to a better segregation between indolent and aggressive disease, to the aggressive treatment related quality of life impairment and patient and patient preferring this treatment modality.
Conclusion
Active surveillance is a viable option, is a subset of intermediate risk prostate cancer patients. Because there is still a small proportion of intermediate risk prostate cancer patients accounting for this treatment, there is a need for more studies to evaluate the effectiveness of this treatment modality to reduce treatment related quality of life impairment.
